Stocks and Investing Stocks and Investing
Mon, December 11, 2023

Gena Wang Maintained (VRTX) at Buy with Increased Target to $415 on, Dec 11th, 2023


Published on 2024-10-28 07:56:16 - WOPRAI, Gena Wang
  Print publication without navigation


Gena Wang of Barclays, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Buy with Increased Target from $408 to $415 on, Dec 11th, 2023.

Gena has made no other calls on VRTX in the last 4 months.



There are 7 other peers that have a rating on VRTX. Out of the 7 peers that are also analyzing VRTX, 3 agree with Gena's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Paul Matteis of "Stifel" Reiterated at Hold and Held Target at $373 on, Wednesday, November 22nd, 2023
  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Increased Target to $364 on, Wednesday, November 8th, 2023
  • Brian Abrahams of "RBC Capital" Maintained at Hold with Decreased Target to $347 on, Tuesday, November 7th, 2023


These are the ratings of the 4 analyists that currently disagree with Gena


  • Olivia Brayer of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $380 on, Tuesday, December 5th, 2023
  • Evan Seigerman of "BMO Capital" Maintained at Buy with Increased Target to $415 on, Tuesday, November 7th, 2023
  • Eric Schmidt of "Cantor Fitzgerald" Reiterated at Buy and Held Target at $370 on, Tuesday, October 17th, 2023
  • Robyn Karnauskas of "Truist Securities" Reiterated at Strong Buy and Held Target at $456 on, Wednesday, October 4th, 2023
Contributing Sources